wolf 10

TB-500 (10 mg Vial) Dosage Protocol

TB‑500 is a synthetic peptide fragment corresponding to the active region of thymosin beta‑4 (Tβ4), a naturally occurring 43‑amino‑acid protein involved in tissue repair and regeneration^[1]^[2]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for accurate insulin‑syringe measurements in research settings.

Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
Typical daily range: 500–1000 mcg once daily (gradual titration recommended).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U‑100 insulin syringe.
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution.

Educational guide for reconstitution and weekly dosing

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Phase	Daily Dose (mcg)	Units (per injection) (mL)
Weeks 1–2	500 mcg	15 units (0.15 mL)
Weeks 3–4	600 mcg	18 units (0.18 mL)
Weeks 5–8	750 mcg	23 units (0.23 mL)
Weeks 9–12	1000 mcg	30 units (0.30 mL)

Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection units in a comfortable range for accurate measurement. Total weekly dose averages ~5 mg, consistent with research protocols^[3]^[4].

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label with date and concentration; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. TB‑500 is not FDA‑approved for human use and is for research purposes only.

Plan based on an 8–16 week daily protocol with gradual titration.

Peptide Vials (TB‑500, 10 mg each):
- 8 weeks ≈ 4 vials
- 12 weeks ≈ 7 vials
- 16 weeks ≈ 10 vials
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 12 weeks (7 vials): 21 mL → 3 × 10 mL bottles
- 16 weeks (10 vials): 30 mL → 3 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes

Concise summary of the once-weekly regimen.

Goal: Support tissue repair, wound healing, and angiogenesis through the active thymosin beta‑4 fragment mechanism^[5]^[6].
Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if research goals require).
Dose Range: 500–1000 mcg daily with gradual titration (~5 mg/week average).
Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid freeze–thaw cycles of reconstituted solution.

Suggested weekly titration approach from clinical trials.

Start: 500 mcg daily; increase by ~100–150 mcg every 2 weeks as tolerated.
Target: 750–1000 mcg daily by Weeks 5–12.
Frequency: Once per day (subcutaneous).
Cycle Length: 8–12 weeks; optional extension to 16 weeks based on research protocol.
Timing: Any consistent time daily; rotate injection sites systematically.

Proper storage preserves peptide quality and stability.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure^[7].
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution as freezing can denature peptides.
Allow vials to reach room temperature before opening to reduce condensation uptake.
Use reconstituted vials within 28 days when stored with bacteriostatic water preservative^[8].

Practical considerations for consistency and safety.

Use new sterile insulin syringes for each injection; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and lipohypertrophy^[9].
Inject slowly; wait a few seconds before withdrawing the needle to prevent backflow.
Document daily dose, injection site, and any observations to maintain consistency.
Regulatory Note: TB‑500 is banned by WADA for athletic use and is not FDA‑approved for human administration^[10].

TB‑500 represents the N‑terminal active fragment of thymosin beta‑4, specifically the heptapeptide sequence Ac‑LKKTETQ^[1]^[2]. This region is responsible for the actin‑binding and cell‑migration properties of the full thymosin molecule. Preclinical studies demonstrate that TB‑500 promotes angiogenesis, accelerates wound healing, and supports tissue regeneration by upregulating cell motility and blood vessel formation^[5]^[6]. Research in animal models shows enhanced collagen deposition and reduced healing time in injury sites treated with thymosin fragments^[11]. Recent metabolic studies suggest TB‑500 may act as a prodrug, cleaving to an active pentapeptide metabolite that drives biological activity^[12].

Observations from preclinical and veterinary literature.

Supports accelerated wound healing and tissue repair through enhanced angiogenesis and cell migration^[5]^[6].
May reduce inflammation and fibrosis indirectly via thymosin pathways observed in animal models^[11].
Generally well tolerated in veterinary studies; occasional mild injection‑site reactions (redness, tenderness) reported.
Human safety data is limited; no large‑scale clinical trials have been completed for TB‑500 specifically^[13].

Complementary strategies for optimal metabolic outcomes.

Maintain adequate protein intake to support tissue repair and regeneration processes.
Combine with appropriate physical activity; avoid overtraining during injury recovery phases.
Prioritize sleep (7–9 hours) to maximize natural recovery and repair mechanisms.
Manage stress levels through evidence‑based practices to support overall healing.

General subcutaneous guidance from clinical best‑practice resources^[14]^[15].

Clean the vial stopper and skin with alcohol; allow to air dry completely.
Pinch a skinfold at the injection site; insert the needle at 45–90° into subcutaneous tissue^[14].
Do not aspirate for subcutaneous injections; inject slowly and steadily^[14].
Rotate sites systematically within approved areas (abdomen, thighs, upper arms) to avoid lipohypertrophy^[9].
Wait 5–10 seconds after injection before withdrawing needle to prevent medication leakage.

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. TB‑500 is not approved by the FDA for human use and is for research purposes only. TB‑500 is a prohibited substance in competitive sports under WADA regulations.

References

— Biological activities of thymosin β4 defined by active peptide sequences (TB‑500 fragment identification)

— Doping control analysis of TB‑500 as synthetic thymosin β4 fragment in biological samples

— Investigation of TB‑500 metabolism, synthesis of metabolites, and detection limits

— Thymosin β4 regulatory bulletin (TB‑500 use in equine sports medicine)

— Thymosin beta4 accelerates wound healing (preclinical wound healing model)

— Active site mapping of thymosin β4 fragments for angiogenesis and cell migration

— Lyophilized peptide storage best practices (temperature, humidity, light protection)

— Bacteriostatic water injection guidelines (0.9% benzyl alcohol, multi‑dose vial stability)

— Best practices for subcutaneous injection (aseptic technique, site rotation)

— TB‑500 classification as prohibited substance in competitive sports

— Thymosin β4 wound healing mechanisms (collagen deposition, angiogenesis, granulation tissue)

— Quantification of TB‑500 metabolites and wound healing activity screening (prodrug hypothesis)

— Clinical trial registry for thymosin β4 in acute myocardial infarction (no TB‑500 specific trials)

— How to administer subcutaneous injections (clinical technique guidelines)

— Patient education guide for subcutaneous injection technique

— TB‑500 (10 mg) product page (purity specifications and batch documentation)

Mechanism Breakdown — 3rd Party Analysis

This video provides an external overview on TB-500.

External Source

Titration schedule.

Standard research titration model. Adjust under qualified clinical observation only. Not for human therapeutic use.

Phase 01

Wk 1 — 4

15 units

Once daily

Initiation · tolerance assessment

Phase 02

Wk 5 — 8

18 units

Once daily

Standard titration step

Phase 03

Wk 9 — 12

23 units

Once daily

Maintenance evaluation

Phase 04

Wk 13+

30 units

Once daily

Optional research extension

Research use only.

TB 500 is supplied strictly for in-vitro laboratory research and biochemical analysis. It is not intended for human consumption, diagnostic use, veterinary application or therapeutic administration of any kind.

Handling must be performed by qualified personnel in compliance with applicable institutional and jurisdictional safety standards. The information contained on this protocol sheet is provided for educational and reference purposes only and does not constitute medical advice.

Not for human use
Store at 2–8 °C, protected from light

Reconstitute under aseptic conditions
Document all research observations

Research use only.

Reta20 is supplied strictly for in-vitro laboratory research and biochemical analysis. It is not intended for human consumption, diagnostic use, veterinary application or therapeutic administration of any kind.

Not for human use
Store at 2–8 °C, protected from light

Reconstitute under aseptic conditions
Document all research observations

wolf 10

TB-500 (10 mg Vial) Dosage Protocol

TB-500 (10 mg Vial) Dosage Protocol

Table of Contents

Quickstart Highlights

Dosing & Reconstitution Guide

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Reconstitution Steps

Supplies Needed

Protocol Overview

Dosing Protocol

Storage Instructions

Important Notes

How This Works

Potential Benefits & Side Effects

Lifestyle Factors

Injection Technique

Video

Important Note

References

Mechanism Breakdown — 3rd Party Analysis

Titration schedule.

Phase 01

Wk 1 — 4

15 units

Once daily

Initiation · tolerance assessment

Phase 02

Wk 5 — 8

18 units

Once daily

Standard titration step

Phase 03

Wk 9 — 12

23 units

Once daily

Maintenance evaluation

Phase 04

Wk 13+

30 units

Once daily

Optional research extension

Research use only.

Research use only.